Physician profile
Manuel G Bloom
NPI 1023029089
$20,089.14
in general payments reported to CMS, 2019-2025
40 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,262 · 2020: $2,805 · 2021: $2,972 · 2022: $4,419 · 2023: $2,941 · 2024: $2,428 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,631.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,097.74 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,798.07 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Actelion Pharmaceuticals US, INC. | $2,498.26 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,960.80 | 2019-2025 | Ofev |
| Genzyme Corporation | $970.66 | 2019-2024 | |
| United Therapeutics Corporation | $897.93 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $843.21 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $797.21 | 2019-2024 | Yupelri |
| Shionogi INC | $704.76 | 2020-2025 | Fetroja |
| Mallinckrodt Hospital Products INC. | $658.68 | 2020-2024 | Acthar |
| Baxter Healthcare | $620.97 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $538.43 | 2019-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $506.79 | 2020-2024 | Cuvitru, Aralast |
| Advanced Respiratory, INC | $392.07 | 2019-2021 | |
| Grifols USA, LLC | $380.19 | 2019-2025 | Prolastin-C Liquid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $274.57 | 2019-2024 | Keytruda, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $261.28 | 2019-2024 | |
| Pfizer INC. | $236.66 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $227.28 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $150.81 | 2022-2024 | Purified Cortrophin Gel |
| Abbvie INC. | $141.29 | 2023-2024 | Teflaro |
| Jazz Pharmaceuticals INC. | $139.94 | 2019-2024 | |
| Genentech USA, INC. | $131.56 | 2019-2020 | |
| Electromed, INC. | $81.86 | 2023-2024 | Smartvest |
| Mallinckrodt Enterprises LLC | $80.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $76.75 | 2021 | |
| Inogen, INC. | $72.86 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Shire North American Group INC | $72.55 | 2019 | |
| Resmed Corp | $61.70 | 2019 | |
| Gilead Sciences, INC. | $59.46 | 2019 | |
| Pharming Healthcare, INC. | $51.05 | 2023-2024 | Ruconest |
| Genentech, INC. | $47.95 | 2020 | |
| Circassia INC. | $47.25 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $44.61 | 2022-2023 | Nuzyra |
| Amgen INC. | $43.41 | 2022-2023 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $31.62 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $26.74 | 2023 | Uptravi, Opsumit |
| Viatris Specialty LLC | $25.76 | 2025 | Yupelri |
| Itamar Medical INC | $18.78 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.32 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.